GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, securing gamgertamig, a potential first-in-class T cell engager for autoimmune diseases. The deal splits the $1.675 billion upfront payment and up to $500 million in milestones equally between the partners; Gilead retains worldwide commercialization rights outside of Keymed’s territories.
Key figures
- Deal Value Usd
- 1675000000
- Program opt in cost
- $75 million
- Gild milestone share
- $250 million
- Lakefront royalty rate
- 20%-23%
- Total milestone payments
- $500 million
- Gild upfront payment share
- $837.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.